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ABSTRACT 49 
The mRNA expression signatures associated with the ‘pro-inflammatory’ phenotype of 50 
depression, and the differential signatures associated with depression subtypes and the 51 
effects of antidepressants, are still unknown. We examined 130 depressed patients (58 52 
treatment-resistant, 36 antidepressant-responsive, and 36 currently untreated) and 40 53 
healthy controls from the BIODEP study, and used whole blood mRNA qPCR to 54 
measure the expression of 16 candidate mRNAs, some never measured before: 55 
interleukin (IL)-1-beta, IL-6, TNF-alpha, macrophage inhibiting factor (MIF), 56 
glucocorticoid receptor (GR), SGK1, FKBP5, the purinergic receptor P2RX7, CCL2, 57 
CXCL12, c-reactive protein (CRP), alpha-2-macroglobulin (A2M), acquaporin-4 (AQP4), 58 
ISG15, STAT1 and USP-18. All genes but AQP4, ISG15 and USP-18 were differentially 59 
regulated. Treatment-resistant and drug-free depressed patients had both increased 60 
inflammasome activation (higher P2RX7 and proinflammatory cytokines/chemokines 61 
mRNAs expression) and glucocorticoid resistance (lower GR and higher FKBP5 62 
mRNAs expression), while responsive patients had an intermediate phenotype with, 63 
additionally, lower CXCL12. Most interestingly, using binomial logistics models we found 64 
that a signature of six mRNAs (P2RX7, IL-1-beta, IL-6, TNF-alpha, CXCL12 and GR ) 65 
distinguished treatment-resistant from responsive patients, even after adjusting for other 66 
variables that were different between groups, such as a trait- and state-anxiety, history 67 
of childhood maltreatment and serum CRP. Future studies should replicate these 68 
findings in larger, longitudinal cohorts, and test whether this mRNA signature can 69 
identify patients that are more likely to respond to adjuvant strategies for treatment-70 
resistant depression, including combinations with anti-inflammatory medications. 71 
72 
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INTRODUCTION  73 
 74 
While there is overwhelming evidence of increased inflammation in depression 1–4, the 75 
molecular signature underpinning this ‘pro-inflammatory’ phenotype is still unknown. A 76 
multitude of studies and meta-analyses show that patients with major depressive 77 
disorder (MDD) have, on average, increased serum levels of pro-inflammatory 78 
cytokines, like interleukin 1 beta  (IL-1-beta), IL-6, and tumour necrosis factor alpha 79 
(TNF-alpha), and of the acute phase protein, C-reactive protein (CRP) 1,2,4,5. Patients 80 
with ‘treatment resistant depression’ (TRD) are more likely to have increased 81 
inflammation 6,7, as do patients with cardiovascular disorders, obesity, anxiety, and a 82 
history of childhood maltreatment 3,8–13. 83 
 84 
Whole blood mRNA expression analyses measure mRNAs coding for inflammatory 85 
genes and for genes operating upstream and downstream of these immune 86 
mechanisms, such as the glucocorticoid receptor (GR) 14. We have been the first to 87 
demonstrate that drug-free depressed patients have increased mRNA expression of IL-88 
1-beta, IL-6 and TNF-alpha, together with reduced expression of the GR and increased 89 
expression of the FK506 binding protein 5 (FKBP5) 15, which reduces GR function and 90 
promotes inflammation 16. Together, these results suggest that inflammation in 91 
depression is potentially caused by escape of the immune system from the anti-92 
inflammatory effects of glucocorticoid hormones (glucocorticoid resistance) as well as 93 
the pro-inflammatory effects of FKBP5 16. Interestingly, we have also found that patients 94 
who do not respond to antidepressants have, before starting the antidepressant, higher 95 
levels of IL-1-beta, macrophage inhibiting factor (MIF) and TNF-alpha mRNAs, 96 
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compared with antidepressant-responsive patients 15,17. Separately, we have found 97 
increased mRNA expression of the GR-target gene, SGK1, in the blood of depressed 98 
patients, in human hippocampal cells treated with cortisol, and in the hippocampus of 99 
rats exposed to stress, thus indicating that mRNA in the human blood can reflect 100 
changes in the brain 18.  101 
 102 
Other blood mRNA studies on depressed patients have measured the whole genome, 103 
rather than focusing on a set of candidate genes, and have consistently found pro-104 
inflammatory signatures. In one of the first such studies, Savitz et al. 19 measured 105 
mRNA expression in peripheral blood mononuclear cells of depressed patients and 106 
identified differentially-expressed mRNAs that were linked to inflammatory pathway, 107 
such as nuclear factor kappa-B (NFkb), transforming growth factor beta (TGFb), and 108 
extracellular signal-regulated kinase (ERK). In the Netherlands Study of Depression and 109 
Anxiety (NESDA), Jansen et al. found an upregulation of IL-6- and natural killer cell-110 
related related pathways 20. Mellon et al. found over-expression of genes involved in 111 
Type I interferon responses, antimicrobial responses, and cytokine and chemokine 112 
signalling 21, and we have recently found over-expression of genes specialised for 113 
innate immunity and myeloid cells 22. Two studies using RNAseq have found differential 114 
regulation of type I interferon-related pathways 23,24, with one study also showing 115 
enrichment for several other pathways involving immune function 23. Finally, a very 116 
recent study has used genome-wide DNA methylation and gene expression analyses in 117 
patients prospectively-defined as responders and non-responders to an 8-week trial of 118 
escitalopram treatment 25, and found two genes that exhibited increases in both DNA 119 
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methylation and mRNA expression in non-responders: CHN2, which could affect 120 
hippocampal neurogenesis, and JAK2, which activates both innate and adaptive 121 
immunity. 122 
 123 
In order to understand the specific molecular signatures associated with TRD vs. 124 
responsive depression, and their interaction with antidepressant treatment, in the 125 
present study we use whole blood mRNA qPCR to measure the expression of 16 126 
candidate mRNAs in 130 depressed patients (58 TRD, 36 antidepressant-responsive, 127 
and 36 currently drug-free) and 40 healthy controls. We have recently published, in an 128 
overlapping sample, that only TRD patients have increased inflammation as measured 129 
as body mass index (BMI)-adjusted CRP 3. Thus, here we hypothesise that TRD 130 
patients have the strongest mRNA-based evidence of inflammation and glucocorticoid 131 
resistance, as shown by higher expression of IL-1-beta, IL-6, TNF-alpha and MIF, 132 
together with lower GR, higher FKBP5 and higher SGK1 expression. Moreover, and  133 
examining mRNA expression of genes hitherto unmeasured in psychiatric patients, we 134 
hypothesise that this increased inflammation is associated with: higher expression of 135 
the purinergic receptor, P2RX7, which mediates stress-induced activation of the 136 
inflammasome 26; higher CCL2 and lower CXCL12 expression, as in the well-137 
established animal model of ‘repeated social defeat’ (RSD) stress, characterised by 138 
increased inflammation and glucocorticoid resistance 27; higher expression  of CRP and 139 
of the other acute phase protein, alpha-2-macroglobulin (A2M) 4,28; and higher 140 
expression of the interferon-responsive genes, acquaporin-4 (AQP4), ISG15, STAT1 141 
and USP-18, which we have recently shown to be elevated in the blood mRNA of 142 
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patients with chronic viral hepatitis taking IFN-alpha 29, an established model of 143 
inflammation-induced depression 30,31,  and to mediate the IFN-alpha-induced increase 144 
in neuronal apoptosis and decrease in neurogenesis 32. Finally, to explore the clinical 145 
implications of these findings, we examined which genes would best classify depressed 146 
subjects in either TRD or antidepressant-responsive, even after adjusting for the effects 147 




METHODS  152 
 153 
Study design and clinical measures 154 
 155 
In total, 190 cases of major depressive disorder, meeting SCID-based DSM-5 criteria for 156 
a diagnosis for major depressive disorder 33, and 54 healthy controls, were recruited in 157 
the non-interventional, case-control, Biomarkers of Depression (BIODEP) study 3; 130 158 
depressed patients and 40 healthy controls with available gene expression data are 159 
included in the present study. The cases were divided into 3 sub-groups based on 160 
current depressive symptom scores at the Hamilton Rating Scale for Depression (HAM-161 
D), and current and previous drug treatment: 1) responsive patients had no depressive 162 
symptoms (HAM-D < 7) while currently on an antidepressant at standard therapeutic 163 
dose for at least 6 weeks; 2) drug-free had depressive symptoms (HAM-D > 17) and 164 
had not been medicated with any antidepressants for at least 6 weeks; and 3) TRD 165 
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patients had depressive symptoms (HAM-D  > 13) while currently on an antidepressant 166 
at standard therapeutic dose for at least 6 weeks, plus they had at least one historical 167 
failure to a different antidepressant. Lifetime antidepressants use was measured using 168 
the Antidepressant Treatment Response Questionnaire (ATRQ) 34, anxiety using the 169 
Spielberger State-Trait Anxiety Rating scale 35, and exposure of stressors in childhood 170 
using the Childhood Trauma Questionnaire (CTQ) 36.  171 
 172 
The study was part of the Wellcome Trust Consortium for Neuroimmunology of Mood 173 
Disorder and Alzheimer’s disease (NIMA), approved by the National Research Ethics 174 
Service East of England, Cambridge Central, UK (15/EE/0092). The study was 175 
conducted according to the Declaration of Helsinki, and all participants provided 176 
informed consent in writing.  177 
 178 
Clinical and sociodemographic features of the sample 179 
 180 
Inclusion and exclusion criteria are presented in the Supplementary Material. The 181 
demographic and clinical characteristics of each group are summarized in Table 1. We 182 
had n=58 TRD patients, n=36 responsive patients, n=36 drug-free patients and n=40 183 
healthy controls. Briefly, all the main within-group comparisons were similar to those 184 
already published in the larger sample 3, and the groups did not differ significantly in 185 
age, gender distribution, educational level and BMI. As expected by design, each group 186 
differed significantly from the others on HAM-D total score (ANOVA, F=683.6; df=3, 187 
166; P<0.001), with drug-free (HAM-D around 20) being more depressed than TRD 188 
 10
(HAM-D around 18), and both being more depressed than responsive (HAM-D around 189 
3) and controls (HAM-D less than 1). Moreover, both TRD and drug-free patients had 190 
higher state and trait anxiety compared with responsive and controls (ANOVA, F=51.2 191 
and 114.5, respectively; df=3, 166; P<0.001). Finally, all patient groups had higher CTQ 192 
scores than controls, and both TRD and untreated patients had higher CTQ scores than 193 
responsive (GLM, Wald chi-square=106.6; df=1, 3; P<0.001).  194 
 195 
Similar to the published larger sample 3, the majority of TRD patients were currently 196 
taking selective serotonin reuptake inhibitors (72%), with smaller numbers exposed to 197 
noradrenergic and specific serotonergic reuptake inhibitors (14%), mirtazapine (9%), 198 
tricyclic antidepressants (4%) or bupropion (1%). Treatment-responsive patients were 199 
also predominantly taking selective serotonin reuptake inhibitors (69%), followed by 200 
noradrenergic and specific serotonergic reuptake inhibitors (22%) and mirtazapine (9%). 201 
Drug-free patients were all currently not on antidepressants for at least 6 weeks; 202 
however, n=20 (55% of the group) had been on an antidepressant in the past, mostly 203 
(17 out of 20) on a selective serotonin reuptake inhibitor.  As expected, the TRD group 204 
had more failed treatments than the other depressed groups (average of 1.7 vs. 0.8 in 205 




Venous blood was sampled from an antecubital vein between 08:00-10:00 h on the day 210 
of clinical assessment. Participants had fasted for 8 h, refrained from exercise for 72 h, 211 
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and had been lying supine for 0.5 h prior to venepuncture. Whole blood (2.5 mL) was 212 
collected in PaxGene tubes at each recruitment site, and all PaxGene tubes were then 213 
kept at -80 °C and later transferred to a central site (Brescia) for RNA isolation and gene 214 
expression analyses. Isolation of total RNA was performed using the PAXgene blood 215 
miRNA kit according to the manufacturer’s protocol (PreAnalytiX, Hombrechtikon, CHE). 216 
RNA quantity and quality were assessed by evaluation of the A260/280 and A260/230 217 
ratios using a Nanodrop spectrophotometer (NanoDrop Technologies, Delaware, USA) 218 
and by Agilent BioAnalyzer (Agilent Technologies); the RNA integrity number (RIN) was 219 
above 8 for all sample. Samples were stored at -80 °C until processing. 220 
 221 
Candidate gene expression analyses was performed using real-time PCR. For quality 222 
control, all samples were assayed in duplicate, and were randomized in different plates, 223 
also adding a calibrator, in order to control for possible differences in the efficiency of 224 
the Real Time reaction. Each target gene was normalized to the expression of three 225 
reference genes (glyceraldehyde 3-phosphate dehydrogenase, beta-actin, and beta-2-226 
microglobulin). We used commercially-available Taqman primer and probes by using 227 
Taqman assays that are all available at the Thermofisher website 228 
(https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-pcr-229 
assays/taqman-gene-expression.html) on a 384 wells Real Time PCR System (Biorad); 230 
the assays had been already tested for efficiency by Thermo Fisher Scientific; catalogue 231 
numbers are available on request. The expression levels of each target gene were 232 
normalized to the geometric mean of all three reference genes, and the Pfaffl method 233 
was used to determine relative target gene expression of each gene in the patients’ 234 
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groups compared with controls. The analyses were conducted by researchers who were 235 
blind to group allocation.  236 
 237 
Methods for the immune assessments are described in the Supplementary Material. 238 
Statistical analyses 239 
 240 
Socio demographic, clinical and immune measurements were compared among the four 241 
study groups by ANOVA, Chi-Square or Generalized linear model (GLM) according to 242 
the statistical distribution of the variables (respectively, Gaussian, categorical, and non-243 
Gaussian). Group mean comparisons of the 16 genes were evaluated by ANOVA test 244 
followed by post-hoc comparisons with Bonferroni correction. Correlations among the 245 
genes, as well as between genes and immune measures, were evaluated by 246 
Spearman’s rho coefficient. Binomial and multinomial logistic regression models were 247 
performed to detect the best predictors of the ‘study group’ outcome variable while 248 
adjusting for the effects of the other variables that were significantly different among the 249 
study groups in previous analyses. A stepwise-forward selection procedure was applied 250 
for the selection of the best (in terms of goodness of fit) predictors of the categorical 251 
‘study group’ outcome, and predictive performances were evaluated by the Negelkerke 252 
pseudo-Rsquare goodness of fit index. Partial Least Square-Discriminant Analysis 253 
(PLS-DA) was conducted to define which genes contributed to discriminate between 254 
each study groups 37,38; the contribution of each variable (gene) in the group 255 
discrimination was displayed by the loadings plots 39. The data-reduction technique, 256 
Principal Component Analysis (PCA), was used to derive, through the biplot, a graphical 257 
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representation of the association between genes and subjects, labelled by study group 258 
(see Supplementary Material). 259 
 260 
 261 
RESULTS  262 
 263 
TRD patients and drug-free depressed patients have the strongest signatures of 264 
inflammation and glucocorticoid resistance 265 
 266 
TRD and drug-free depressed patients had increased levels of circulating serum CRP 267 
(see Table 1), as previously reported in the overlapping sample 3. Specifically, CRP was 268 
higher in TRD patients compared with responsive and controls, and in drug-free patients 269 
compared with controls (GLM, Wald Chi2=40.5; P<0.001). Numerically, CRP was higher 270 
in TRD patients (average of 5 mg/L), followed by drug-free (2.9 mg/L), followed by 271 
responsive (2.2 mg/L), with controls averaging at around 1.1 mg/L. There were also 272 
significant differences in total white cell count (ANOVA, F3,164=4.09; P=0.008) and 273 
absolute number of neutrophils (ANOVA, F3,164=3.3; P=0.022): both were significantly 274 
higher in TRD patients compared with controls, and the gradient present for CRP 275 
(TRD>drug-free>responsive>controls) was present also for these measures. 276 
  277 
Thirteen of the 16 genes were significantly different among the four groups (see Table 278 
2, ANOVAs and post-hoc comparisons with Bonferroni correction). In general, TRD and 279 
drug-free patients had similarly increased levels of inflammation-related genes: this 280 
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applied to both the genes that had been measured before in depression (IL1-beta, IL-6, 281 
TNF-alpha, MIF) and those never measured before (A2M, CRP, P2RX7, CCL2 and 282 
STAT1). Moreover, TRD and drug-free patients also showed similar evidence of 283 
glucocorticoid resistance (lower GR and higher FKBP5 expression). Responsive 284 
patients had an intermediate phenotype with only some of these genes (IL-6, MIF, TNF-285 
alpha and A2M, as well as FKBP5) different from controls. 286 
 287 
Contrary to our primary hypothesis that TRD patients would have the strongest 288 
evidence of inflammation and glucocorticoid resistance, none of the above genes were 289 
significantly higher in TRD compared with drug-free patients; indeed, CCL2 was 290 
significantly higher in drug-free than in TRD patients (see Table 2). This suggests that 291 
TRD and drug-free patients came, at least in part, from phenotypically similar groups 292 
(see Discussion).  293 
 294 
Interestingly, SGK1 was significantly higher only in the drug-free group, while TRD and 295 
responsive patients had levels similar to controls. Thus, albeit elevated in depression as 296 
we hypothesised, SGK1 levels were not linked with glucocorticoid resistance, since they 297 
were normal in TRD patients even if they had low GR mRNAs (see also correlation 298 
analyses below).  299 
 300 
It is also of note that both P2RX7 and CXCL12 were lower in the responsive group 301 
compared with controls. For CXCL12, this confirms our hypothesis, based on the RSD 302 
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animal model 27, that this gene would be reduced in (at least some) patients with 303 
depression.  304 
 305 
The three genes that were not differentially regulated were three of the four interferon-306 
responsive genes, AQP4, ISG15, and USP-18.  307 
 308 
The correlation matrix (Spearman’s rho) for 13 differentially expressed genes together 309 
with serum CRP and immune cell counts is presented in Figure 1. There were 310 
significant, positive correlations between P2RX7, pro-inflammatory cytokines, and 311 
FKBP5 mRNAs, and significant negative correlations between all of these genes and 312 
GR mRNA. Moreover, white cell and neutrophil counts were (not-significantly) positively 313 
correlated with FKBP5 (rh0=0.20/0.21) and negatively correlated with GR mRNA (rho=-314 
0.21/-0.22). Together, these correlations indicate that, as hypothesised, the 315 
inflammasome/inflammatory gene over-expression and resulting immune activation are 316 
associated with glucocorticoid resistance and with FKBP5-mediated pro-inflammatory 317 
signalling. Interestingly, GR was negatively correlated with FKBP5, but neither was 318 
correlated with SGK1, confirming that SGK1 is not a marker of GR resistance. It is also 319 
of note that serum CRP (largely produced by the liver) was significantly, positively 320 
correlated with CRP mRNA (from the whole blood). 321 
 322 
Binomial logistic models show that a signature comprising P2RX7, IL-1-beta, IL-6, 323 
TNF-alpha, CXCL12 and GR, discriminates between TRD and responder patients 324 
over and above standard clinical and blood immune assessments 325 
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 326 
Binomial logistics models were performed applying the step-forward procedure, in order 327 
to examine the predicting performance of mRNA gene expression, clinical data and 328 
blood immune variables, in classifying depressed patients in the TRD or responders 329 
study group, while addressing the co-variance between the immune genes and 330 
adjusting for all the other clinical and immune variables. (see Table 3).  331 
 332 
The first model included the six clinical and immune variables significantly different 333 
between the study groups (see Table 1): State Anxiety, Trait Anxiety, Total score CTQ, 334 
CRP, total white cells, and neutrophils numbers. HAM-D and number of failed 335 
antidepressants were excluded as these were part of the decisional process leading to 336 
group allocation. Trait Anxiety and neutrophils numbers were the only significant 337 
predictors, with a Nagelkerke’ pseudo-R-squared equal to 0.53.  338 
 339 
The second model included the 13 significant genes from the univariate analyses (see 340 
ANOVA in Table 2). Ten genes were significant predictors (P2RX7, IL-1b, IL-6, MIF, 341 
TNF-alpha, CCL2, CXCL12, GR, FKBP5, and STAT1), with a Nagelkerke’ pseudo-R-342 
squared =0.89.  343 
 344 
Finally, the third model included the two significant variables from model 1 (Trait Anxiety 345 
and neutrophils number) and the 10 significant genes from model 2. It resulted in six 346 
genes (P2RX7, IL-1-beta, IL-6, TNF-alpha, CXCL12 and GR) remaining the only 347 
significant predictors, with a Nagelkerke’ pseudo-R-squared =0.90. Thus, the 348 
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expressions of these 6 genes remain significant predictors of the allocation of 349 
depressed patients to the TRD or responders group even after adjusting for the other 350 
clinical and immune variables, whose variability was fully captured by Trait Anxiety and 351 
neutrophils number, and with a larger predictive ability than the standard clinical and 352 
immune variables in Model 1 (Nagelkerke’ pseudo-R-squared =0.90 vs. 0.53).  353 
 354 
A second series of multinomial logistics models were performed to examine the 355 
predicting performance of gene expression, clinical data and blood immune variables, in 356 
classifying all study subjects in the four study groups, including drug-dree depressed 357 
patients and controls (see Supplementary Results and Supplementary Table 1). We 358 
found that a signature of five mRNAs (P2RX7, IL-6, GR, SGK1 and TNF-alpha) together 359 
with Trait Anxiety significantly predicted the allocation of subjects to their study group.   360 
 361 
Partial least square discriminant analyses show that P2RX7 best discriminates 362 
TRD patients vs. all other patients, while GR best discriminates responsive vs. all 363 
other depressed patients 364 
 365 
The partial least square discriminant analysis (PLSDA) is presented in Figure 2. This 366 
was conducted to define which genes mainly contribute to discriminate between each of 367 
the four groups or between the three patient groups. Panel A (on the three depressed 368 
groups only) shows that: P2RX7, and, less, CXCL12 and IL-1-beta (all in red), best 369 
discriminate TRD vs the other depressed groups; CCL2, and, less, FKBP5 and MIF (all 370 
in green),  best discriminate drug-free vs the other depressed groups; and GR, and, 371 
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less, IL-6 and A2M (all in blue), best discriminate responsive vs the other depressed 372 
groups. Panel B (on the four groups) shows GR (in black) as the gene that best 373 
discriminates controls from all the other depressed groups. It is worth noting that the 374 
discriminant performance of some genes overlaps on more than one patient group, as 375 
also indicated by the principal component analysis (PCA) of the 13 differentially 376 
expressed genes presented in Supplementary Material (Figure S1).   377 
DISCUSSION  378 
 379 
In a study examining whole blood mRNA expression of candidate genes in depressed 380 
patients characterised for their depressive symptoms and response to antidepressants, 381 
and testing both established and hitherto unmeasured mRNAs, we find evidence of 382 
inflammasome activation and glucocorticoid resistance in both drug-free depressed 383 
patients and antidepressant-treated TRD patients (less so in antidepressant-treated 384 
responsive patients). Moreover, a mRNAs signature of six genes (P2RX7 and CXCL-12, 385 
both measured for the first time in psychiatric patients, as well as IL-1-beta, IL-6, TNF-386 
alpha and GR) is a significant predictor of allocation of depressed patients to the TRD or 387 
responder group in binomial logistics models, even after adjusting for other clinical 388 
variables that are different between groups, such as a history of childhood maltreatment 389 
and serum CRP. 390 
 391 
Our data confirm our previous findings showing increased whole blood mRNA 392 
expression of IL-6, MIF and TNF-alpha in depressed patients vs. controls 15, with higher 393 
levels of IL-1-beta and MIF predicting TRD when measured in drug free-depressed 394 
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patients before starting an antidepressant treatment 15,17. This consistency is particularly 395 
noticeable since the above-mentioned studies are clinical trials with a pre-post 396 
assessment 15,17, and thus the biomarkers were measured before starting the 397 
antidepressants (at a time where patients were all drug-free and their response status 398 
was still unknown) and the response was measured prospectively. Admittedly, this was 399 
a much better design than the present study, which instead compares patients allocated 400 
to different groups based on a combination of current symptomatology and medication 401 
use as well historical treatment response. As shown in Table 1, these leads to groups 402 
that are different in a number of biological and clinical risk factors. All things considered, 403 
it is thus reassuring that we replicate both the increased IL-6, MIF and TNF-alpha in all 404 
our depressed groups vs. controls, as well as the increased IL-1-beta, TNF-alpha and 405 
MIF in TRD vs. responsive.   406 
 407 
Meta-analyses of longitudinal studies have shown that antidepressant treatment (on 408 
average, for 6-12 weeks) is associated with decreases in serum or plasma cytokines, 409 
such as IL-6 and TNF-alpha, both in general 40 and for SSRIs in particular 41, with the 410 
most recent meta-analyses showing that TNF-alpha, but not IL-6, is differentially 411 
affected in responders only 42. Data on longitudinal changes in mRNA expression are 412 
much more limited; for example, we published 15 that 8-weeks of antidepressants 413 
(escitalopram or nortriptyline) decrease IL-6 mRNA, but this is driven by responders 414 
only, while TNF-alpha mRNA levels do not change. In the present study we find that 415 
levels of IL-6 and TNF-alpha mRNAs are higher in responders than controls, although 416 
with slightly different patterns, that is, responders have the highest IL-6 (higher even 417 
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than TRD) while TNF-alpha is lower than in TRD patients. However, it is important to 418 
emphasise that it is difficult to compare the present study with all the others, because of 419 
the cross-sectional, rather than longitudinal, nature of our study: we simply do not know 420 
what the cytokines levels in these patients were before they started the antidepressants.  421 
 422 
P2RX7 is a purinergic receptor that activates the NLR family pyrin domain containing 3 423 
(NLRP3), a pattern-recognition receptor that precipitates the pro-inflammatory cascade 424 
26,43. P2RX7 is ubiquitously expressed in cells of the immune system 44, but recent 425 
research has identified its expression also in neuronal cells, where it regulates the 426 
function of neurotransmitters relevant to depression 45. In our study, P2RX7 is not only 427 
associated with other markers of inflammation and with GR expression, as 428 
hypothesised, but it is also the strongest predictors of TRD in the PLSDA, and one of 429 
the predictive genes in the signature originated by the binomial and multinomial models. 430 
While one previous study found increased levels of NLRP3 in the monocytes of 431 
depressed patients 46, the only evidence so far of a direct involvement of P2RX7 in 432 
depression comes from genetic studies associating a polymorphism in the gene with 433 
severity of depressive symptoms 45,47. 434 
 435 
We replicate here our previous findings showing reduced GR mRNA and higher  FKBP5 436 
mRNA in depressed patients 15. While increased FKBP5 expression is well known to 437 
induce glucocorticoid resistance 48,49, new evidence indicates that FKBP5 can also 438 
directly promote inflammation by strengthening the interactions of NF-κB regulatory 439 
kinases 16, and our findings showing that pro-inflammatory genes are positively 440 
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correlated with FKBP5 expression confirm these functional links. Indeed, the ultimate 441 
role of the reduced GR mRNA in our findings is difficult to define, as most clearly 442 
exemplified by the fact that responsive patients have GR levels indistinguishable from 443 
controls yet have increased IL-6, MIF, TNF-alpha and A2M levels. Moreover, recent 444 
data from the larger BIODEP sample show that only drug-free patients have increased 445 
cortisol levels 50, but we show here that both drug-free and TRD have reduced GR 446 
mRNA. While the concept of reduced GR function and expression leading to 447 
‘glucocorticoid resistance’ in depression has been extensively discussed before  51–55, 448 
including for TRD patients 56–58, the present study shows that reduced GR mRNA 449 
expression alone cannot fully explain the increased inflammation. Indeed the 450 
aforementioned study by Mellon et al. 21 found upregulation of immune pathways in 451 
mononuclear cells from depressed patients in the absence of changes in GR function, 452 
and our own clinical meta-analysis on this topic has found only limited evidence linking 453 
‘glucocorticoid resistance’ to inflammation 59. Furthermore, it is important to emphasise 454 
here the additional confounding effects of antidepressant treatment. Previous studies 455 
have shown that antidepressants increase the expression and the function of the GR in 456 
experimental and clinical models 51,53,60,61, and we have also found that GR mRNA 457 
levels are increased by antidepressants in the aforementioned longitudinal mRNA gene 458 
expression study, irrespective of response 15. In the present study, we find that GR 459 
mRNA levels are ‘normal’ in responsive patients but lower in TRD, even if both groups 460 
have similar profiles of antidepressant treatment. In contrast, we find increased levels of 461 
the GR-target gene, SGK1, in drug-free depressed patients but not in antidepressant-462 
treated (TRD and responsive) patients, and Frodl et al. also measured SGK1 mRNA in 463 
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depressed patients who were mostly on antidepressants and found no differences 464 
compared with controls 62. As mentioned above, the lack of longitudinal data in the 465 
present study makes it difficult to dissect the differential effects of antidepressant 466 
treatment vs. clinical improvement on mRNAs expression. 467 
 468 
CCL2 and CXCL12 are chemokines involved in the RSD model of depression, 469 
characterised by increased inflammation and glucocorticoid resistance 27. These mice 470 
show increased CCL2 in circulation and increased levels of the receptor for CCL2, C-C 471 
chemokine receptor type 2 (CCR2), in the brain, leading to monocyte recruitment to the 472 
brain and increased microglia activation. Consistently, we find increased CCL2 mRNA 473 
expression in TRD and drug-free patients, and other studies found elevated serum 474 
CCL2 (also known as Monocyte chemoattractant protein 1, MCP-1) in depressed 475 
patients 63. Interestingly, in the present study we find lower levels of CCL2 in TRD 476 
patients than in drug-free patients (even if both are higher than in controls), and we 477 
have previously found, in a different sample, lower levels of serum CCL2 (MCP-1) in 478 
TRD vs. responsive patients 64. Thus, it is possible that lower CCL2 in depression 479 
identifies a more severe, TRD group. Differently from CCL2, CXCL12 inhibits the 480 
trafficking of monocytes to the circulation, and in fact CXCL12 levels are reduced in the 481 
RSD model 55. A recent meta-analysis did not find any studies measuring CXCL12 in 482 
depression 63, but it is interesting that we find reduced CXCL12 in responsive depressed 483 
patients in our study (and normal levels in the other depressed groups), showing some 484 
consistency with the RSD model. 485 
 486 
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Both CRP and A2M mRNAs are elevated in TRD and drug-free depressed patients in 487 
our study. There is an extensive literature showing elevated levels of serum (protein) 488 
CRP in depression, with more than 13 thousand patients included in recent meta-489 
analyses 2,4 and evidence of increased CRP also in the cerebrospinal fluid 65. 490 
Interestingly, while the liver is considered the most important source of CRP, CRP 491 
mRNA has been detected in macrophages from the lung 66 and from atherosclerotic 492 
plaques 67. Our study not only finds that CRP mRNA is expressed in circulating blood 493 
cells, but also that the whole blood CRP mRNA is highly correlated with the levels of 494 
(liver-produced) serum CRP protein. A2M is another acute phase protein, like CRP, but 495 
there are only three studies looking at A2M serum levels in depression, with conflicting 496 
findings 68–70. We have recently described higher A2M mRNA in both whole blood 497 
mRNA of adult humans exposed to early life trauma and the hippocampus of adult rats 498 
exposed to prenatal stress, and identified 7 polymorphisms in the A2M gene that show 499 
significant gene x environment interactions with childhood stress in predicting 500 
depressive symptoms in adulthood 28. Together, this evidence supports a role of A2M in 501 
depression, but further studies are needed.  502 
 503 
Finally, we measure here the four interferon-responsive genes, acquaporin-4, ISG15, 504 
STAT1 and USP-18, which are elevated in the whole blood 29 and in human neurones 505 
following IFN-alpha 32. Only STAT1 is increased in the present study, in both drug-free 506 
and TRD patients, suggesting that the upregulation of the other three genes is only 507 
visible after pharmacological inflammation induced by IFN-alpha, or in brain tissue. 508 
Although this is the first study measuring STAT1 in the blood of depressed patients, the 509 
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above-mentioned studies in the NESDA cohort 20 and in non-responders to citalopram 510 
25 found an upregulation of, respectively, STAT3 and JAK2 mRNAs, and another study 511 
found STAT3 cell signalling alterations in depression 71.  512 
 513 
The study has two main limitations that must be discussed. Firstly, as mentioned above, 514 
this is not a clinical trial with pre-post measures of gene expression or longitudinal 515 
ascertainment of antidepressant resistance, and thus cross-sectional comparisons 516 
between groups are likely to be influenced by other clinical and sociodemographic 517 
variables that differ between groups. Of course, our analyses attempt to adjust for such 518 
group differences in the binomial/multinomial logistic regression models. Moreover, we 519 
had already measured the mRNA levels of seven of the 16 genes (IL-1-beta, IL-6, TNF-520 
alpha, MIF, GR, FKBP5 and SGK1) in drug-free depressed patients 15 and in 521 
‘prospectively-defined’ TRD patients 15,17,18, and in the present paper we replicate all of 522 
these findings. Nevertheless, the cross-sectional design of the present study implies 523 
that, especially for the genes never measured before, the findings need to be replicated. 524 
The second important limitation is that the measurement of mRNA gene expression is in 525 
the whole blood rather than sorted immune cells. Of course, the ‘whole-blood’ approach 526 
has the advantages of speed and simplicity of blood collection and handling ‘at the 527 
bedside’, which is essential for the development of clinically useful biomarkers. 528 
However, we do not know which cells predominantly contributes to the mRNA findings, 529 
and furthermore we lack functional cellular data, for example, to measure 530 
inflammasome activation or glucocorticoid resistance. Thus, future studies should 531 
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include an in-depth characterisation of immune cells-specific mRNA profiles as well as 532 
functional methodologies.  533 
 534 
Notwithstanding these limitations, we believe that our paper is relevant to novel 535 
approaches for personalised psychiatry and novel targets for immune-related 536 
antidepressants therapies. We find that a combination of six genes (P2RX7, IL-1-beta, 537 
IL-6, TNF-alpha, CXCL-12 and GR) performs better than the routine clinical and 538 
immunological variables in identifying patients who are TRD or responsive to 539 
antidepressants. If replicated in larger, longitudinal samples, this signature might be 540 
helpful in identifying patients that should be fast-tracked into augmentation regimes – 541 
potentially a step toward overcoming the classic ‘trial and error’ approach in treating 542 
depression. In terms of novel targets, antagonists of P2RX7 72, JAK 73, CCR2 74 and 543 
FKBP5 16 are all novel antidepressant tools supported by our findings. Future studies 544 
will need to examine if these new treatments work, and whether responses to such new 545 
treatments can be improved by selecting patients with abnormal levels of relevant 546 
mRNAs. 547 
 548 
  549 
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FIGURE LEGENDS  841 
 842 
Figure 1: Correlations (Spearman’s rho) between significantly-different genes and 843 
immune measures 844 
 845 
Coloured coefficients are statistically different from zero at level p<0.05; red = negative 846 
correlations, blue=positive correlations.  847 
 848 
 849 
Figure 2: Partial Least Squares Discriminant analysis outputs: loading plots 850 
 851 
The partial least square discriminant analysis (PLSDA) was conducted to define which 852 
genes contribute to discriminate between each of the four groups. The plots depict the 853 
loadings of each gene: the larger the loading, the better the gene discriminates the 854 
study group from the others. Loadings summarize how the genes are related to each 855 
other as well as discriminate between the groups: all genes with positive loadings are 856 
positive correlated with each other and negatively correlated with genes with negative 857 
loadings; colours indicate the group for which the genes have a maximal median value. 858 
Panel A (on the three depressed groups only) shows that: P2RX7, and, less, CXCL12 859 
and IL-1-Beta (all in red), best discriminate TRD vs the other depressed groups; CCL2, 860 
and, less, FKBP5 and MIF (all in green), best discriminate drug-free vs the other 861 
depressed groups; and GR, and, less, IL-6 and A2M (all in blue), best discriminate 862 
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responsive vs the other depressed groups. Panel B (on the four groups) shows GR (in 863 
black) is the gene that best discriminates controls from all the other depressed groups.  864 
 865 
 866 
  867 
 868 
  869 
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Table 1. Demographic, clinical and immune data 870 
  Mean [95% confidence interval] / N (%) in category Group test 

















Statistic P-value Post Hoc # 









F=0.43 0.73  
Gender, female, N 
[%] 






















=14.6 0.26  
Relationship status 
[Divorced, 















=21.6 0.01  























F=51.19 <0.001 Con<others 












F=114.5 <0.001 Con<others 
Resp vs others 






























0.27   



























=2.8 0.83  
























F=2.35 0.073  















Total White Cells 5.9 [5.5-
6.4] 














F=2.65 0.051  





















F=3.30 0.022 TRD>Con 































# Post-Hoc: “specific group category vs others” means that the specific group has mean score 872 
statistically different (larger or smaller) than the scores of others group categories;  873 
“one group >/< one group” means that the first category group has score statistically 874 
larger/smaller than the second group. 875 
  876 
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Table 2. Candidate gene expression data 877 








































































































































































































# Post-Hoc: “one group >/< one group” means that the first category group has score 879 
statistically larger/smaller than the second group. 880 
 881 
 882 
  883 
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Table 3: Binomial regression models output for detecting the best predictors of 884 

























State-Anxiety 0.4(1) 0.533 
CRP 0.2 (1) 0.961 
Neutrophils absolute 5.9 (1) 0.015 
Total White Cells 0.3 (1) 0.601 












CCL2 4.9 (1) 0.023 
IL-1beta 3.8 (1) 0.048 
IL-6 3.6 (1) 0.037 
GR 18.4 (1) <0.001 
P2RX7 11.5 (1) 0.003 
SGK1 2.2 (1) 0.125 
TNF-alpha 3.7 (1) 0.042 
FKBP5  4.5 (1) 0.004 
A2M  2.1 (1) 0.076 
MIF   6.1 (1) 0.018 
STAT1  5.6 (1) 0.009 






Mod. iii) # 






P2RX7 14.0 (1) <0.001 
TNF-alpha 4.1 (1) 0.040 
Trait-Anxiety 3.9 (1) 0.051 
IL-6 4.2 (1) 0.042 
CCL2   3.8 (1) 0.053 
IL-1beta   6.6 (1) 0.010 
CXCL12 5.7 (1) 0.031 
Neutrophils absolute 1.2 (1) 0.277 
FKBP5 2.4 (1) 0.124 
MIF 2.5 (1) 0.113 
STAT1   1.4 (1) 0.235 
 
887 
# Explanatory variables of the model iii) were standardized in order to take into account the different 888 
variable ranges. 889 
Mod.i) considering only (significantly different between group) clinical and blood immune variables; mod 890 
ii) considering only (significantly different between group) genes variables; mod iii) considering both 891 
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Inclusion and exclusion criteria  
 
Patients were recruited from the UK National Health Service mental health, primary care 
services and from the general population by purposive advertising, while controls were 
recruited by purposive advertising. For all participants, the following inclusion criteria 
applied: age 25–50 years; able to give informed consent and understand English; able 
to fast for 8 h and abstain from strenuous exercise for 72 h prior to venous blood 
sampling. The following exclusion criteria applied: pregnancy or breast feeding, alcohol 
or substance use disorder in the preceding 12 months, participation in an investigational 
drug study within the preceding 12 months, lifetime history of any medical disorder or 
current use of any medication (e.g., statins, corticosteroids, antihistamines, anti-
inflammatory medications) likely to compromise interpretation of immune measures, and 
lifetime histories of bipolar disorder or non-affective psychosis. Healthy controls had no 
current or past history of any major psychiatric disorder as defined by DSM-5, and no 
history of monoaminergic drug treatment for any indications.  
 
Standard immune assessments  
 
High-sensitivity CRP was measured using a Turbidimetry methods on Beckman Coulter 
AU analyzers, with rabbit anti-CRP-antibodies coated on latex particles. Absolute 
counts of total white blood cells, lymphocytes, neutrophils, monocytes, eosinophils and 
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Multinomial logistics models were performed to examine the predicting performance of 
gene expression, clinical data and blood immune variables, in classifying subjects in in 
the four study groups (see Supplementary Table 1), while addressing the co-variance 
between the immune genes and adjusting for all the other clinical and immune 
variables.  
 
The first model included the six clinical and immune variables significantly different 
between the study groups (see Table 1): State Anxiety, Trait Anxiety, Total score CTQ, 
CRP, total white cells, and neutrophils numbers. HAM-D and number of failed 
antidepressants were excluded as these were part of the decisional process leading to 
group allocation. Only Trait Anxiety resulted as the strongest significant predictor, (i.e. 
the best predictor resulted by applying the step-forward procedure), with a Nagelkerke’ 
pseudo-R-squared equal to 0.67.  
 
The second model included the 13 significant genes from ANOVA (see Table 2). The 
application of the step-forward procedure returned 8 genes as significant predictors of 
the group variable (IL1b, IL-6, TNF-alpha, CCL2, CXCL12, GR, P2RX7, SGK1) with a 
Nagelkerke’ pseudo-R-squared =0.97.  
 
Finally, in the third model including Trait Anxiety and the 8 significant genes resulted 
from the previous models, five genes (IL-6, GR, P2RX7, SGK1, TNF-alpha) and Trait 
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anxiety remain significant, with a Nagelkerke’ pseudo-R-squared =0.94. Thus, the 
expressions of these 5 genes remain significant predictors of the four study groups even 
after adjusting for the other clinical and immune variables, whose variability was fully 
captured by Trait Anxiety, and with a larger predictive ability than the standard clinical 
and immune variables in Model 1 (Nagelkerke’ pseudo-R-squared =0.94 vs. 0.67).  
 
 
The Principal Component Analysis for the set of 13 differentially expressed 
mRNAs shows that the partition between groups is driven by the contrast 
between higher pro-inflammatory mRNAs expression, mainly associated with 
TRD and drug-free patients, and higher GR expression, mainly associated with 
controls and responders 
 
We used the data-reduction technique Principal Component Analysis (PCA) to derive, 
through the biplot, a graphical representation of the association between genes and 
subjects, labelled by study group.  
 
PCA for the set of 13 differentially expressed genes is presented in Supplementary 
Figure 1. As mentioned in the Methods, this was performed to derive a graphical 
representation of the association between genes and subjects labelled by study group. 
There was a partial overlap between TRD patients (in green) and drug-free patients (in 
blue), as well as a clear separation between these two groups and the control (in light 
pink) and responders (in violet). This partition between groups is consistent with the 
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results of the univariate analyses (see main paper), and it is driven by the contrast 
between higher pro-inflammatory gene expression, mainly associated with TRD and 
drug-free patients, and higher GR expression, mainly associated with controls and 




Supplementary Table 1 
Multinomial logistic regression models output for detecting the best predictors of 

























State-Anxiety 5.5 (3) 0.137 
CRP 2.1 (3) 0.554 
Neutrophils absolute 6.8 (3) 0.080 
Total White Cells 2.5 (3) 0.474 












CCL2 38.9 (3) <0.001 
IL-1beta 24.8 (3) <0.001 
IL-6 35.5 (3) <0.001 
GR 68.4 (3) <0.001 
P2RX7 61.5 (3) <0.001 
SGK1 47.0 (3) <0.001 
TNF-alpha 16.0 (3) 0.001 
FKBP5 3.3 (3) 0.352 
A2M 1.8 (3) 0.611 
MIF 1.1 (3) 0.782 
STAT1 0.6 (3) 0.898 
CRP 0.1 (3) 0.990 
 
 
Mod. iii) # 





P2RX7 32.1 (3) <0.001 
SGK1 54.9 (3) <0.001 
TNF-alpha 28.5 (3) <0.001 
Trait-Anxiety 65.6 (3) <0.001 
IL-6 17.3 (3) 0.001 
CCL2 6.6 (3) 0.098 
IL-1beta 6.1 (3) 0.101 
CXCL12 4.4 (3) 0.221 
 
# Explanatory variables of the model iii) were standardized in order to take into account 
the different variable ranges. Model i) considering only significant (see Table 1) clinical 
and blood immune variables; Model ii) considering only significant (see Table 2) genes 
variables; Model iii) considering both genes and clinical-blood immune variables 
resulted significant in Mod. i)  and Mod ii).  
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Supplementary Figure 1  





Principal component (PC) analysis for the set of 13 differentially expressed genes was 
performed to derive a graphical representation of the association between genes and 
subjects labelled by study group. There was a partial overlap between TRD patients (in 
red) and drug-free patients (in green), as well as a clear separation between these two 
groups and the control (in black) and responders (in blue). This partition between 
groups is consistent with the results of the univariate analyses (see Table 2) of the PLS-
DA, and it is driven by the contrast between higher pro-inflammatory gene expression, 
mainly associated with TRD and drug-free patients, and higher GR expression, mainly 
associated with controls and responders.  Arrows represent the variables (genes) and 
points represent the subjects labelled by study groups. 
